Browse > Article

Papillary Thyroid Carcinoma in Renal Allograft Recipients  

Lee, Jan-Dee (Department of Surgery, Ajou University College of Medicine)
Hong, Hyeop (Department of Surgery, Ajou University College of Medicine)
Jeong, Jong-Ju (Department of Surgery, Yonsei University College of Medicine)
Nam, Kee-Hyun (Department of Surgery, Yonsei University College of Medicine)
Chung, Woong-Youn (Department of Surgery, Yonsei University College of Medicine)
Soh, Euy-Young (Department of Surgery, Ajou University College of Medicine)
Park, Cheong-Soo (Department of Surgery, Yonsei University College of Medicine)
Publication Information
Korean Journal of Head & Neck Oncology / v.24, no.1, 2008 , pp. 64-68 More about this Journal
Abstract
Purpose：The chronic use of immunosuppressive therapy in transplant recipients can increase the long-term risk of carcinoma. The aim of this study was to determine the incidence, biological behaviors, and treatment outcomes in PTC(papillary thyroid carcinoma) in renal allograft recipients. Material and Methods：The present study examined the incidence and biological behavior of PTCs in RA recipients. A total of 1,739 RA patients treated between January 1986 and December 1999 were followed-up for a median 137(84-238) months. During the follow-up period, 129(7.4%) recipients were identified as having posttransplant malignancies. Of those, 12(0.7%) had PTCs, and these comprised six male and six female patients with a median age of 41(23-57) years. Results：Nine cases(incidentalomas) were diagnosed based on ultrasonography(US) screening. Eight of those nine were TNM stage I, and two of the three clinical carcinomas were TNM stage IVa. During a median follow-up of 94(18-159) months, two(16.7%) PTC patients developed loco-regional recurrence, but no patients showed distant metastasis. Posttransplant PTC showed no gender bias, and was often associated with aggressive lymphatic metastasis. However, most incidentalomas showed a favorable treatment outcome. Conclusion：In conclusion, routine surveillance of the thyroid gland using US screening is recommended to ensure early detection, treatment and favorable prognosis in RA patients with PTC.
Keywords
Posttransplant malignancy; PTC(papillary thyroid carcinoma); Renal allograft;
Citations & Related Records
연도 인용수 순위
  • Reference
1 London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP: Risk of neoplasia in renal transplant patients. Lancet. 1995;346:403-406   DOI   ScienceOn
2 Brunner FP, Landais P, Selwood NH: Malignancies after renal transplantation: the EDTA-ERA registry experience. European Dialysis and Transplantation Association-European Renal Association. Nephrol Dial Transplant. 1995;10:74-80
3 First MR, Peddi VR: Malignancies complicating organ transplantation. Transplant Proc. 1998;30:2768-2770   DOI   ScienceOn
4 Pond F, Serpell JW, Webster A: Thyroid cancer in the renal transplant population: epidemiological study. ANZ J Surg. 2005; 75:106-109   DOI   ScienceOn
5 Schwartz RS: Immunoregulation, oncogenic viruses, and malignant lymphomas. Lancet. 1972;1:1266-1269
6 Fahey TJ 3rd, Reeve TS, Delbridge L: Increasing incidence and changing presentation of thyroid cancer over a 30-year period. Br J Surg. 1995;82:518-520   DOI   ScienceOn
7 Samhan M, Al-Mousawi M, Donia F, Fathi T, Nasim J, Nampoory MR: Malignancy in renal recipients. Transplant Proc. 2005;37:3068-3070   DOI   ScienceOn
8 Veroux M, Puliatti C, Fiamingo P, et al: Early de novo malignancies after kidney transplantation. Transplant Proc. 2004;36: 718-720   DOI   ScienceOn
9 Franceschi S, La Vecchia C: Thyroid cancer. Cancer Surv. 1994; 19-20:393-422
10 Keast D: Immunosurveillance and cancer. Lancet. 1970;2:710-712
11 Wang CX, Liu LS, Chen LZ, et al: Characteristics of neoplasm occurrence and the therapeutic effect of Sirolimus in South Chinese kidney transplant recipients. Transplant Proc. 2006;38:3536-3539   DOI   ScienceOn
12 Shah JP: AJCC Cancer Staging Handbook. TNM classification of malignant tumors, 6th ed. In: Greene FL(ed) Springer-Verlag, New York, 2002:77-78
13 Penn I: Cancer is a complication of severe immunosuppression. Surg Gynecol Obstet. 1986;162:603-610
14 Hoshida Y, Aozasa K: Malignancies in organ transplant recipients. Pathol Int. 2004;52:649-658
15 Korea Central Cancer Registry Working Group: Korea Cancer Statistics: 1996 Incidence. Seoul. GA: Department of Disease Control and Prevention Services. National Health Insurance Cooperation and Nation Cancer Institute, 2004.Korean cancer Survellence, 2007:1190
16 Nemes B, Zalatnai A, Podder H, et al: Papillary microcarcinoma of the thyroid gland in renal transplant patients. Pathol Oncol Res. 2000;6:72-75   DOI
17 Nafar M, Einollahi B, Hemati K, Gholi FP, Firouzan A: Development of malignancy following living donor kidney transplantation. Transplant Proc. 2005;37:3065-3067   DOI   ScienceOn
18 Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905-913   DOI   ScienceOn
19 Suzuki T, Takano Y, Yamashita K, Sato K, Kakita A, Okudaira M: A possible role for Epstein-Barr virus in tumorigenesis after immunosuppression in cases of renal transplantation. J Cancer Res Clin Oncol. 1993:119:627-629   DOI
20 Penn I: Cancers following cyclosporine therapy. Transplantation. 1987;43:32-35   DOI   ScienceOn